{"id":2444,"date":"2017-01-01T12:06:00","date_gmt":"2017-01-01T11:06:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2017\/sglt-2-hemmer-bereits-ueber-2000-gemeldete-faelle-mit-azidosen"},"modified":"2022-03-17T14:13:30","modified_gmt":"2022-03-17T13:13:30","slug":"sglt-2-hemmer-bereits-ueber-2000-gemeldete-faelle-mit-azidosen","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2017\/sglt-2-hemmer-bereits-ueber-2000-gemeldete-faelle-mit-azidosen","title":{"rendered":"SGLT-2-Hemmer: Bereits \u00fcber 2000 gemeldete &#8222;F\u00e4lle&#8220; mit Azidosen"},"content":{"rendered":"<p>Da die Natrium-Glukose-Cotransporter-2(SGLT2)-Inhibitoren (Dapagliflozin, Empagliflozin, Canagliflozin) stark beworben und zunehmend zur Behandlung von Typ-2-Diabetikern angewendet werden, sei erneut auf das erh\u00f6hte Risiko von Ketoazidosen hingewiesen. Neben zunehmenden Fallberichten (1-3) und Warnhinweisen bzw. Informationsbriefen von Institutionen (4-6) ergab eine Abfrage der EudraVigilance-Datenbank der europ\u00e4ischen Arzneimittel-Agentur EMA (7), dass international \u00fcber 2.000 F\u00e4lle mit Azidosen unter einer [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Da die Natrium-Glukose-Cotransporter-2(SGLT2)-Inhibitoren (Dapagliflozin, Empagliflozin, Canagliflozin) stark beworben und zunehmend zur Behandlung von Typ-2-Diabetikern angewendet werden, sei erneut auf das erh\u00f6hte Risiko von Ketoazidosen hingewiesen. Neben zunehmenden Fallberichten (1-3) und Warnhinweisen bzw. Informationsbriefen von Institutionen (4-6) ergab eine Abfrage der EudraVigilance-Datenbank der europ\u00e4ischen Arzneimittel-Agentur EMA (7), dass international \u00fcber 2.000 F\u00e4lle mit Azidosen unter einer [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[1554,1553,1556,48,1555,1558,1559,1557,1552,1550,1551],"class_list":["post-2444","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-azidose","tag-canagliflozin","tag-dapagliflozin","tag-diabetes-mellitus","tag-empagliflozin","tag-gliflozine","tag-ketoazidose","tag-natrium-glukose-cotransporter-2","tag-sglt2","tag-sglt2-hemmer","tag-sglt2-inhibitoren"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2444","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=2444"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2444\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=2444"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=2444"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=2444"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}